ATIM-40. CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS PREDICT FAVORABLE RESPONSE TO IMMUNE CHECKPOINT THERAPY IN A RANDOMIZED TRIAL OF NIVOLUMAB AND BEVACIZUMAB IN RECURRENT GBM

Manmeet Ahluwalia; Matthew Grabowski; Tyler Alban; Balint Otvos; Defne Bayik; Anas Saeed Bamashmos; Patricia Rayman; Marcela Diaz-Montero; David Reardon; Patrick Wen; David Peereboom; Justin Lathia

doi:10.1093/NEUONC/NOZ175.039

ATIM-40. CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS PREDICT FAVORABLE RESPONSE TO IMMUNE CHECKPOINT THERAPY IN A RANDOMIZED TRIAL OF NIVOLUMAB AND BEVACIZUMAB IN RECURRENT GBM

Manmeet Ahluwalia, Matthew Grabowski, Tyler Alban, Balint Otvos, Defne Bayik, Anas Saeed Bamashmos, Patricia Rayman, Marcela Diaz-Montero, David Reardon, Patrick Wen, David Peereboom, Justin Lathia

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
DOIs	https://doi.org/10.1093/NEUONC/NOZ175.039
State	Published - Nov 11 2019
Event	Neuro-oncology - Duration: Nov 11 2019 → …

Conference

Conference	Neuro-oncology
Period	11/11/19 → …

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1093/NEUONC/NOZ175.039License: Unspecified

Cite this

Ahluwalia, M., Grabowski, M., Alban, T., Otvos, B., Bayik, D., Bamashmos, A. S., Rayman, P., Diaz-Montero, M., Reardon, D., Wen, P., Peereboom, D., & Lathia, J. (2019). ATIM-40. CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS PREDICT FAVORABLE RESPONSE TO IMMUNE CHECKPOINT THERAPY IN A RANDOMIZED TRIAL OF NIVOLUMAB AND BEVACIZUMAB IN RECURRENT GBM. Neuro-oncology. https://doi.org/10.1093/NEUONC/NOZ175.039

Ahluwalia, M, Grabowski, M, Alban, T, Otvos, B, Bayik, D, Bamashmos, AS, Rayman, P, Diaz-Montero, M, Reardon, D, Wen, P, Peereboom, D & Lathia, J 2019, 'ATIM-40. CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS PREDICT FAVORABLE RESPONSE TO IMMUNE CHECKPOINT THERAPY IN A RANDOMIZED TRIAL OF NIVOLUMAB AND BEVACIZUMAB IN RECURRENT GBM', Neuro-oncology, 11/11/19. https://doi.org/10.1093/NEUONC/NOZ175.039

@conference{3d2caa7ad0814bd3a3a99ef40081b6e7,

title = "ATIM-40. CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS PREDICT FAVORABLE RESPONSE TO IMMUNE CHECKPOINT THERAPY IN A RANDOMIZED TRIAL OF NIVOLUMAB AND BEVACIZUMAB IN RECURRENT GBM",

author = "Manmeet Ahluwalia and Matthew Grabowski and Tyler Alban and Balint Otvos and Defne Bayik and Bamashmos, \{Anas Saeed\} and Patricia Rayman and Marcela Diaz-Montero and David Reardon and Patrick Wen and David Peereboom and Justin Lathia",

year = "2019",

month = nov,

day = "11",

doi = "10.1093/NEUONC/NOZ175.039",

language = "American English",

note = "Neuro-oncology ; Conference date: 11-11-2019",

}

TY - CONF

T1 - ATIM-40. CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS PREDICT FAVORABLE RESPONSE TO IMMUNE CHECKPOINT THERAPY IN A RANDOMIZED TRIAL OF NIVOLUMAB AND BEVACIZUMAB IN RECURRENT GBM

AU - Ahluwalia, Manmeet

AU - Grabowski, Matthew

AU - Alban, Tyler

AU - Otvos, Balint

AU - Bayik, Defne

AU - Bamashmos, Anas Saeed

AU - Rayman, Patricia

AU - Diaz-Montero, Marcela

AU - Reardon, David

AU - Wen, Patrick

AU - Peereboom, David

AU - Lathia, Justin

PY - 2019/11/11

Y1 - 2019/11/11

UR - https://academic.oup.com/neuro-oncology/article-abstract/21/Supplement_6/vi10/5620312

U2 - 10.1093/NEUONC/NOZ175.039

DO - 10.1093/NEUONC/NOZ175.039

M3 - Presentation

T2 - Neuro-oncology

Y2 - 11 November 2019

ER -

ATIM-40. CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS PREDICT FAVORABLE RESPONSE TO IMMUNE CHECKPOINT THERAPY IN A RANDOMIZED TRIAL OF NIVOLUMAB AND BEVACIZUMAB IN RECURRENT GBM

Conference

Disciplines

Access to Document

Other files and links

Cite this